Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrea J Korecki

Showing results (1-10 of 22) with videos related to

Pageof 3
Sort By:
Investigative Ophthalmology & Visual Science|July 23, 2025
Establishing Preclinical Quantitative Parameters for Future Assessment of Corneal and Retinal Therapeutics for AniridiaSif G Kaad, Andrea J Korecki, Elizabeth M Simpson
Gene Therapy|April 18, 2023
rAAV-PHP.B escapes the mouse eye and causes lethality whereas rAAV9 can transduce aniridic corneal limbal stem cells without lethalitySeyedeh Zeinab Mirjalili Mohanna, Andrea J Korecki, Elizabeth M Simpson
Human Molecular Genetics|February 6, 2018
Human cis-acting elements regulating escape from X-chromosome inactivation function in mouseSamantha B Peeters, Andrea J Korecki, Elizabeth M Simpson, et al.
Gene Therapy|January 4, 2019
Correction: Epistasis between Pax6<sup>Sey</sup> and genetic background reinforces the value of defined hybrid mouse models for therapeutic trialsJack W Hickmott, Uvini Gunawardane, Kimberly Jensen, et al.
Gene Therapy|September 28, 2018
Epistasis between Pax6<sup>Sey</sup> and genetic background reinforces the value of defined hybrid mouse models for therapeutic trialsJack W Hickmott, Uvini Gunawardane, Kimberly Jensen, et al.
Gene Therapy|March 9, 2026
First pilot study of intravenous rAAV-PAX6 gene therapy increases retinal-ganglion-cell-layer thickness and Notch1 transcription in a mouse model of aniridiaDiana Djaksigulova, Sif G Kaad, Andrea J Korecki, et al.
Human Molecular Genetics|April 11, 2025
Escape from X-chromosome inactivation at KDM5C is driven by promoter-proximal DNA elements and enhanced by domain contextSamantha Peeters, Sarah Baldry, Andrea J Korecki, et al.
Molecular Therapy. Advances|July 9, 2026
First pilot study of intrastromal rAAV-PAX6 gene therapy suggests improved corneal thickness and transcription correction in aniridic mouseSif G Kaad, Tess C Lengyell, Seyedeh Zeinab Mirjalili Mohanna, et al.
American Journal of Medical Genetics. Part C, Seminars in Medical Genetics|February 20, 2019
How do genes that escape from X-chromosome inactivation contribute to Turner syndrome?Samantha B Peeters, Andrea J Korecki, Sarah E L Baldry, et al.
Human Gene Therapy|February 18, 2025
Minimally Humanized <i>Ezh2</i> Exon-18 Mouse Cell Lines Validate Preclinical CRISPR/Cas9 Approach to Treat Weaver SyndromeWilliam T Gibson, Tess C Lengyell, Andrea J Korecki, et al.
Pageof 3

Showing results (1-10 of 22) with videos related to

Sort By:
Pageof 3
Investigative Ophthalmology & Visual Science|July 23, 2025
Establishing Preclinical Quantitative Parameters for Future Assessment of Corneal and Retinal Therapeutics for AniridiaSif G Kaad, Andrea J Korecki, Elizabeth M Simpson
Gene Therapy|April 18, 2023
rAAV-PHP.B escapes the mouse eye and causes lethality whereas rAAV9 can transduce aniridic corneal limbal stem cells without lethalitySeyedeh Zeinab Mirjalili Mohanna, Andrea J Korecki, Elizabeth M Simpson
Human Molecular Genetics|February 6, 2018
Human cis-acting elements regulating escape from X-chromosome inactivation function in mouseSamantha B Peeters, Andrea J Korecki, Elizabeth M Simpson, et al.
Gene Therapy|January 4, 2019
Correction: Epistasis between Pax6<sup>Sey</sup> and genetic background reinforces the value of defined hybrid mouse models for therapeutic trialsJack W Hickmott, Uvini Gunawardane, Kimberly Jensen, et al.
Gene Therapy|September 28, 2018
Epistasis between Pax6<sup>Sey</sup> and genetic background reinforces the value of defined hybrid mouse models for therapeutic trialsJack W Hickmott, Uvini Gunawardane, Kimberly Jensen, et al.
Gene Therapy|March 9, 2026
First pilot study of intravenous rAAV-PAX6 gene therapy increases retinal-ganglion-cell-layer thickness and Notch1 transcription in a mouse model of aniridiaDiana Djaksigulova, Sif G Kaad, Andrea J Korecki, et al.
Human Molecular Genetics|April 11, 2025
Escape from X-chromosome inactivation at KDM5C is driven by promoter-proximal DNA elements and enhanced by domain contextSamantha Peeters, Sarah Baldry, Andrea J Korecki, et al.
Molecular Therapy. Advances|July 9, 2026
First pilot study of intrastromal rAAV-PAX6 gene therapy suggests improved corneal thickness and transcription correction in aniridic mouseSif G Kaad, Tess C Lengyell, Seyedeh Zeinab Mirjalili Mohanna, et al.
American Journal of Medical Genetics. Part C, Seminars in Medical Genetics|February 20, 2019
How do genes that escape from X-chromosome inactivation contribute to Turner syndrome?Samantha B Peeters, Andrea J Korecki, Sarah E L Baldry, et al.
Human Gene Therapy|February 18, 2025
Minimally Humanized <i>Ezh2</i> Exon-18 Mouse Cell Lines Validate Preclinical CRISPR/Cas9 Approach to Treat Weaver SyndromeWilliam T Gibson, Tess C Lengyell, Andrea J Korecki, et al.
Pageof 3